Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REC 602

X
Drug Profile

REC 602

Alternative Names: HPV Bivalent (Type 6/11) Vaccine - Jiangsu Recbio Technology; HPV-6/11 vaccine - Jiangsu Recbio Technology; REC-602

Latest Information Update: 28 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Recbio Technology
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical cancer; Genital warts

Most Recent Events

  • 21 Mar 2022 New profile triggered from 9352572
  • 07 Jan 2022 Beijing ABZYMO Biosciences has multiple patents protection for methods to create different types of HPV L1 protein with H. polymorpha expression system, in relation to REC 602, in China
  • 07 Jan 2022 Jiangsu Recbio Technology plans to submit BLA to the NMPA in China in 2025
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top